The Paradox of Acute Myeloid Leukemia Responsiveness to Adoptive T-cell Therapy Available to Purchase

Since the recognition of the allogeneic graft-versus-leukemia effect, acute myeloid leukemia (AML) has been identified as a T cell–targetable malignancy, but success with modern forms of immunotherapy has been slower than anticipated. In this issue, we discuss the biological barriers to the treatment of AML with T-cell therapy revealed by recent reports, including mechanistic insights into AML resistance to T cell–mediated killing by Tin and colleagues.

See related article by Tin et al., p. 217